Results 271 to 280 of about 1,467,646 (404)

Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology

Angewandte Chemie, Volume 137, Issue 28, July 7, 2025.
Targeted protein degradation (TPD) has emerged as a powerful therapeutic approach, with numerous candidates molecules now advancing into clinical development. Recent innovations have incorporated nanoparticles to facilitate and enhance these degradation processes, yielding synergistic effects.
Andrew G. Baker, Adrian Pui Ting Ho, Laura S. Itzhaki, Ljiljana Fruk   +3 more
wiley   +2 more sources

Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers. [PDF]

J Immunother Cancer
Kaur M, Rüger K, Chen EC, Rangaswamy US, Davison LM, Moreno Arteaga S, Smith I, Chu R, Chattopadhyay S, Rickert M, Force Aldred S, Harris KE, Trinklein ND, Clarke SC.   +13 more
europepmc   +1 more source

Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy [PDF]

, 2010
Robert M. Sharkey, Edmund A. Rossi, William J. McBride, Chien‐Hsing Chang, David M. Goldenberg   +4 more
openalex   +1 more source

T‐Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B‐Cell Lymphoma

eJHaem, Volume 6, Issue 4, August 2025.
ABSTRACT Background Tumour infiltrating lymphocyte (TIL) T‐cell receptor (TCR) repertoire is prognostic in newly diagnosed diffuse large B‐cell lymphoma (DLBCL), but evolution has not been evaluated at relapse. Methods We examined the TCR repertoire in nine paired DLBCL samples from diagnosis and relapse. Results We noted considerable differences, with
Joel Wight, Tom Witkowski, Colm Keane, Eliza A. Hawkes   +3 more
wiley   +1 more source

Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors. [PDF]

Exp Hematol Oncol
Luo M, Wang X, Yu G, Ji J, Li L, Song F.
europepmc   +1 more source

A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells [PDF]

, 2010
Edmund A. Rossi, Diane L. Rossi, Rhona Stein, David M. Goldenberg, Chien‐Hsing Chang   +4 more
openalex   +1 more source

Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B‐Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review

European Journal of Haematology, Volume 115, Issue 2, Page 104-116, August 2025.
ABSTRACT Objectives The objective of this systematic literature review (SLR) combined with expert clinical review was to identify and rank prognostic factors and effect measure modifiers (EMMs) systematically and comprehensively in patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who initiate treatment after ≥ 2 prior ...
Bastian von Tresckow, Pau Abrisqueta, Irene Zamanillo, Ángel Serna Pareja, Yuting Kuang, Jennifer Uyei, Mohsin Shah, Laura Walsh, Eileen Thorley, Krystal Cantos, Emaan Rashidi, Christian Hampp, Jessica J. Jalbert, Alexi N. Archambault, Yingxin Xu, Shivani Aggarwal, Srikanth Ambati, Hesham Mohamed, Qiufei Ma, Ana Jiménez‐Ubieto   +19 more
wiley   +1 more source

A cell-penetrating bispecific antibody suppresses hepatitis B virus replication and secretion. [PDF]

Virus Res
Xie C, Zhou B, Yao D, Wang X, Zhong L, Qiu C, Zhang J.   +6 more
europepmc   +1 more source

Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F(ab′)₂ antibody [PDF]

, 2010
Frits Aarts, Otto C. Boerman, Robert M. Sharkey, Thijs Hendriks, Chien‐Hsing Chang, William J. McBride, Robert P. Bleichrodt, Wim J.G. Oyen, David M. Goldenberg   +8 more
openalex   +1 more source

NKp30: A Key Membrane Molecule in the Fight Against Cancer and Infection

The FASEB Journal, Volume 39, Issue 14, 31 July 2025.
NKp30 is a crucial activating receptor on the surface of NK cells, mediating NK cell activation or the release of regulatory factors to exert cytotoxic effects by recognizing and binding to corresponding ligands. This article discusses the glycosylation of NKp30 and its pivotal role in antitumor and anti‐infection responses.
Yushu Shao, Yang Zhang, Jiaying Cao, Junyu He, Qian He, Yan Lei, Ning Tang, Yanhong Zhou   +7 more
wiley   +1 more source